Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has announced that its subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has had its drug registration application for Levosalbutamol Hydrochloride Nebuliser Solution accepted by the National Medical Products Administration. This drug is intended for the treatment or prevention of bronchospasm in individuals aged six and older with reversible obstructive airway disease. The company has invested approximately RMB 4.54 million in the drug’s development, and this acceptance marks a significant step in expanding its pharmaceutical offerings in China, potentially impacting its market presence and stakeholder interests.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in the People’s Republic of China, primarily focused on the pharmaceutical industry. The company and its subsidiaries are involved in the development, production, and sale of pharmaceutical products, with a market focus on providing medical and health solutions.
YTD Price Performance: -8.24%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.81B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.
